Lipid Nanoparticles With Fine‐Tuned Composition Show Enhanced Colon Targeting as a Platform for mRNA Therapeutics DOI Creative Commons
Riccardo Rampado, Gonna Somu Naidu, Olga Karpov

и другие.

Advanced Science, Год журнала: 2024, Номер unknown

Опубликована: Ноя. 25, 2024

Abstract Lipid Nanoparticles (LNPs) recently emerged as an invaluable RNA delivery platform. With many LNP‐based therapeutics in the pre‐clinical and clinical pipelines, there is extensive research dedicated to improving LNPs. These efforts focus mainly on tolerability transfectability of new ionizable lipids RNAs, or modulating LNPs biodistribution with active targeting strategies. However, most formulations follow well‐established lipid proportions used clinically approved products. Nevertheless, investigating effects composition their can expand toolbox for particle design, leading improved Herein, a (30‐n‐LNPs) formulation increasing amounts phospholipids investigated possible mRNA system treating Inflammatory Bowel Diseases. Compared benchmark (b‐LNPs), n‐LNPs containing 30% distearoylphosphatidylcholine (DSPC) are well tolerated following intravenous administration display natural toward inflamed colon dextran sodium sulfate (DSS)‐colitis bearing mice, while de‐targeting clearing organs such liver spleen. Using interleukin‐10‐encoding therapeutic cargo, demonstrated reduction pathological burden colitis‐bearing mice. represent starting point further investigate influence systemic biodistribution, ultimately opening modalities different pathologies.

Язык: Английский

Nano–Bio Interactions: Exploring the Biological Behavior and the Fate of Lipid-Based Gene Delivery Systems DOI
Seigo Kimura,

Hideyoshi Harashima

BioDrugs, Год журнала: 2024, Номер 38(2), С. 259 - 273

Опубликована: Фев. 12, 2024

Язык: Английский

Процитировано

5

Current landscape of mRNA technologies and delivery systems for new modality therapeutics DOI Creative Commons
Ruei‐Min Lu,

Hsiang-En Hsu,

Ser John Lynon P Perez

и другие.

Journal of Biomedical Science, Год журнала: 2024, Номер 31(1)

Опубликована: Сен. 10, 2024

Abstract Realizing the immense clinical potential of mRNA-based drugs will require continued development methods to safely deliver bioactive agents with high efficiency and without triggering side effects. In this regard, lipid nanoparticles have been successfully utilized improve mRNA delivery protect cargo from extracellular degradation. Encapsulation in was an essential factor successful application vaccines, which conclusively demonstrated technology's yield approved medicines. review, we begin by describing current advances modifications, design novel lipids nanoparticle components for drugs. Then, summarize key points pertaining preclinical therapeutics. Finally, cover topics related targeted systems, including endosomal escape targeting immune cells, tumors organs use vaccines new treatment modalities human diseases.

Язык: Английский

Процитировано

5

Spleen-targeted nanosystems for immunomodulation DOI
Fazhan Wang,

Jia Lou,

Xiaoke Gao

и другие.

Nano Today, Год журнала: 2023, Номер 52, С. 101943 - 101943

Опубликована: Июль 28, 2023

Язык: Английский

Процитировано

11

Lipoamino bundle LNPs for efficient mRNA transfection of dendritic cells and macrophages show high spleen selectivity DOI

Franziska Haase,

Jana Pöhmerer,

Mina Yazdi

и другие.

European Journal of Pharmaceutics and Biopharmaceutics, Год журнала: 2023, Номер 194, С. 95 - 109

Опубликована: Дек. 6, 2023

Язык: Английский

Процитировано

10

Discovery of peptides for ligand-mediated delivery of mRNA lipid nanoparticles to cystic fibrosis lung epithelia DOI Creative Commons
Melissa Soto, Mae M. Lewis, J. Sánchez Leal

и другие.

Molecular Therapy — Nucleic Acids, Год журнала: 2024, Номер 35(4), С. 102375 - 102375

Опубликована: Окт. 30, 2024

Язык: Английский

Процитировано

4

AKT kinases as therapeutic targets DOI Creative Commons

Dalal Hassan,

Craig W. Menges, Joseph R. Testa

и другие.

Journal of Experimental & Clinical Cancer Research, Год журнала: 2024, Номер 43(1)

Опубликована: Ноя. 29, 2024

Abstract AKT, or protein kinase B, is a central node of the PI3K signaling pathway that pivotal for range normal cellular physiologies also underlie several pathological conditions, including inflammatory and autoimmune diseases, overgrowth syndromes, neoplastic transformation. These pathologies, notably cancer, arise if either activity AKT its positive negative upstream downstream regulators effectors goes unchecked, superimposed on by intersection with slew other pathways. Targeting PI3K/AKT is, therefore, prudent countermeasure. inhibitors have been tested in many clinical trials, primarily combination drugs. While some recently garnered attention their favorable profile, concern over resistance off-target effects continued to hinder widespread adoption clinic, mandating discussion alternative modes targeting. In this review, we discuss isoform-centric targeting may be more effective less toxic than traditional pan-AKT significance disease prevention treatment, immunotherapy. We touch emerging mutant- allele-selective covalent allosteric (CAAIs), as well indirect, novel AKT-targeting approaches, end briefing ongoing quest reliable biomarkers predicting sensitivity response inhibitors, current state affairs.

Язык: Английский

Процитировано

4

Nucleic Acid Delivery Nanotechnologies for In Vivo Cell Programming DOI

Hannia V. Balcorta,

Veronica Guerrero,

Deepali Bisht

и другие.

ACS Applied Bio Materials, Год журнала: 2024, Номер 7(8), С. 5020 - 5036

Опубликована: Янв. 30, 2024

In medicine, it is desirable for clinicians to be able restore function and imbue novel into selected cells therapy disease prevention. Cells damaged by disease, injury, or aging could programmed normal lost functions, such as retinal in inherited blindness neuronal Alzheimer's disease. also genetically with functions immune expressing synthetic chimeric antigen receptors immunotherapy. Furthermore, knockdown modification of risk factor proteins can mitigate development. Currently, nucleic acids are emerging a versatile potent therapeutic modality achieving this cellular programming. review, we highlight the latest developments nanobiomaterials-based acid therapeutics programming from biomaterial design delivery perspective how overcome barriers their clinical translation benefit patients.

Язык: Английский

Процитировано

3

Organ-selective lipid nanoparticles for precise cancer therapy: Beyond liposomes and polymeric micelles DOI
Xu Huang, Yan Ding,

Jia Ming Gu

и другие.

Chemical Engineering Journal, Год журнала: 2024, Номер 494, С. 153171 - 153171

Опубликована: Июнь 15, 2024

Язык: Английский

Процитировано

3

Polymeric nanocarriers for gene delivery DOI Creative Commons
Jiayuan Zhang, Xinyu Yang, Zhenyu Chang

и другие.

Asian Journal of Pharmaceutical Sciences, Год журнала: 2025, Номер 20(1), С. 101015 - 101015

Опубликована: Янв. 5, 2025

The recent commercialization of gene products has sparked significant interest in therapy, necessitating efficient and precise delivery via various vectors. Currently, viral vectors lipid-based nanocarriers are the predominant choices have been extensively investigated reviewed. Beyond these vectors, polymeric also hold promise therapeutic owing to their versatile functionalities, such as improving stability, cellar uptake endosomal escape nucleic acid drugs, along with targeted tissues. This review presents a brief overview status quo emerging for delivery, focusing on key cationic polymers, nanocarrier types, preparation methods. It highlights diseases, strategies improve efficiency, potential future directions this research area. is hoped inspire development, optimization, clinical translation highly delivery.

Язык: Английский

Процитировано

0

Approaches and applications in transdermal and transpulmonary gene drug delivery DOI Creative Commons
Anni Zhang, Xuran Zhang, Jiahui Chen

и другие.

Frontiers in Bioengineering and Biotechnology, Год журнала: 2025, Номер 12

Опубликована: Янв. 15, 2025

Gene therapy has emerged as a pivotal component in the treatment of diverse genetic and acquired human diseases. However, effective gene delivery remains formidable challenge to overcome. The presence degrading enzymes, acidic pH conditions, gastrointestinal mucus layer pose significant barriers for therapy, necessitating exploration alternative therapeutic options. In recent years, transdermal transpulmonary modalities offer promising avenues with multiple advantages, such non-invasion, avoided liver first-pass effect improved patient compliance. Considering rapid development therapeutics via administration, here we aim summarize nearest advances drug delivery. this review, firstly elaborate on current carrier therapy. We, further, describe approaches applications enhancing encompassing microneedles, chemical enhancers, physical methods administration well nebulized formulations, dry powder pressurized metered dose formulations efficient Last but not least, opportunities outlooks through both administrated routes are highlighted.

Язык: Английский

Процитировано

0